

Ref: EPL/CS/SE/0059/2026

Date: July 15, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Board Meeting intimation for approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026

Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, August 06, 2026 *inter-alia* to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026.

The trading window for dealing in securities of the Company by the Designated Persons and their relatives has been already closed from July 01, 2026, as communicated earlier vide our letter No. EPL/CS/SE/0052/2026 dated June 29, 2026 and shall remain closed till 48 hours after the declaration of the Unaudited Financial Results i.e. till August 08, 2026, in terms of the Company's Code of Conduct for regulating, monitoring and reporting of insider trading in the securities of the Company, framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Amruta Yungalwar
Company Secretary & Compliance Officer
ICSI Membership Number: A25687

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251